Barclays
MREO

Barclays’s Mereo BioPharma MREO Stock Holding History

Barclays’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,600
Closed -$2.33K – 5291
2025
Q4 		$2.33K Hold
5,600
– – ﹤0.01% 5035
2025
Q3 		$11.5K Buy
+5,600
New +$10.3K ﹤0.01% 5007

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Barclays's MREO Position: Q1 2026 in Review

Barclays reduced its Mereo BioPharma (MREO) stake by 83% in Q1 2026, selling an estimated $5.15K and leaving 2,496 shares worth $824. The position accounts for ﹤0.01% of the portfolio, ranked #4913.

Barclays first reported a position in MREO in Q2 2019 and has held it in 18 quarters since. The position peaked at $596K in Q4 2021. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Barclays held 2,496 shares of Mereo BioPharma worth $824 as of Q1 2026.
  • Barclays sold 12,004 Mereo BioPharma shares in Q1 2026, an estimated $5.15K.
  • Mereo BioPharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4913 holding.
  • Barclays first reported a position in Mereo BioPharma in Q2 2019 and has held it in 18 quarters since.
  • Barclays's Mereo BioPharma position peaked at $596K in Q4 2021.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.